BioSpace News Archive

LimFlow SA announced today that the U.S. Food and Drug Administration (FDA) has approved the LimFlow System to help people with CLTI who have no other suitable endovascular or surgical treatment options and are facing major amputation.

Alto Neuroscience Inc. today announced Amit Etkin, M.D., Ph.D., founder and chief executive officer, will present at the following investor conferences.

Exelixis, Inc. and Insilico Medicine (“Insilico”) today announced that the companies have entered into an exclusive license agreement granting Exelixis global rights to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1, which has emerged as a synthetic lethal target in the context of BRCA-mutated tumors.

Entera Bio Ltd. (NASDAQ: ENTX, “Entera”) and OPKO Biologics, Inc., a subsidiary of OPKO Health, Inc. (NASDAQ: OPK, “OPKO”) have entered into a Research Collaboration Agreement.

Evolution Optiks Limited, a privately held company specializing in light field technology, announced today the start of a clinical study of its DeCon device for the evaluation of human vestibular disorders.

Vistagen today announced that PH80, one of the Company’s five investigational neuroactive nasal sprays, demonstrated statistically significant improvement versus placebo in an exploratory Phase 2A study for acute management of the symptoms of premenstrual dysphoric disorder (PMDD), including negative mood and physical and behavioral symptoms.

Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus’ chief financial officer, is scheduled to participate at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, at 10:30 a.m. EST.

Spirent has concluded a review of Xona Space Systems’ PULSAR™ production signals establishing feasibility for integration into the SimXona product line.

Perimetrics, Inc., an advanced artificial intelligence (AI) dental diagnostics company, today announced the U.S. Food and Drug Association (FDA) granted clearance for its InnerView® device, including the wireless handpiece, charging base station and disposable tip with embedded smart chips.

NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS) today announced the publication of Prospective study of the effect of auricular percutaneous electrical nerve field stimulation on quality of life in children with pain related disorders of gut-brain interaction, a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of IB-Stim™ in children with post-concussion symptoms, featured in the September 2023 Frontiers in Pain Research.